|Dr. Jan Groen Ph.D.||Chief Exec. Officer, Pres and Exec. Director||704.04k||N/A||57|
|Mr. Jean-Marc Roelandt||Chief Financial Officer and Exec. VP||N/A||N/A||52|
|Dr. Wim Van Criekinge Prof., Ph.D.||Chief Scientific Officer||N/A||N/A||45|
|Mr. Joseph Sollee J.D., LLM||Chief Compliance Officer, Exec. VP of Corp. Devel. and Gen. Counsel||N/A||N/A||52|
|Shalon Roth||Exec. VP of Corp. Communications & Public Affairs||N/A||N/A||N/A|
MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients in Belgium and internationally. The company's tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's products include ConfirmMDx, a solution for prostate cancer testing; and SelectMDx, a pre-biopsy diagnostic tool for prostate cancer. Its product pipeline includes tests for bladder, kidney, and other urologic cancers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.
MDxHealth SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.